Piper Jaffray Starts Eidos Therapeutics (EIDX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts EIDX Hot Sheet
Price: $122.21 --0%
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Piper Jaffray analyst Tyler Van Buren initiates coverage on Eidos Therapeutics (NASDAQ: EIDX) with a Overweight rating and a price target of $55.00.
For an analyst ratings summary and ratings history on Eidos Therapeutics click here. For more ratings news on Eidos Therapeutics click here.
Shares of Eidos Therapeutics closed at $34.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tigress Financial Partners Resumes Southwest (LUV) at Buy
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
- Goldman Sachs Starts Synspective Inc (290A:JP) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
